1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Fatigue - Pipeline Review, H1 2017

Fatigue - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 54 pages

Fatigue - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fatigue – Pipeline Review, H1 2017, provides an overview of the Fatigue (Central Nervous System) pipeline landscape.

Fatigue also referred to as tiredness, exhaustion, lethargy, listlessness, and describes a physical and/or mental state of being tired and weak. Signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fatigue – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fatigue (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fatigue (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 1 and 3 respectively.

Fatigue (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fatigue (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Fatigue (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fatigue (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fatigue (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fatigue (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fatigue (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fatigue (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Fatigue - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fatigue - Overview
Fatigue - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Fatigue - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fatigue - Companies Involved in Therapeutics Development
Aoxing Pharmaceutical Company Inc
BioLite Inc
Biovista Inc
Chronos Therapeutics Ltd
Grifols SA
Hemispherx Biopharma Inc
K-Pax Pharmaceuticals Inc
Merz Pharma GmbH and Co KgaA
MultiCell Technologies Inc
Fatigue - Drug Profiles
(lofepramine hydrochloride + phenylalanine) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
alpha-1 proteinase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BLI-1402 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
caffeine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CTDP-001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
KPAX-002 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
MRZ-9547 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Recombinant A1PI - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Fatigue - Dormant Projects
Fatigue - Product Development Milestones
Featured News and Press Releases
Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME
Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen
Jul 25, 2016: Hemispherx Announces First Shipment of Rintatolimod (Ampligen) to Early Access Program in Europe
Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology
May 23, 2016: Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke
Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen
Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms
Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe
Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations
May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations
May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fatigue, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fatigue - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
Fatigue - Pipeline by BioLite Inc, H1 2017
Fatigue - Pipeline by Biovista Inc, H1 2017
Fatigue - Pipeline by Chronos Therapeutics Ltd, H1 2017
Fatigue - Pipeline by Grifols SA, H1 2017
Fatigue - Pipeline by Hemispherx Biopharma Inc, H1 2017
Fatigue - Pipeline by K-Pax Pharmaceuticals Inc, H1 2017
Fatigue - Pipeline by Merz Pharma GmbH and Co KgaA, H1 2017
Fatigue - Pipeline by MultiCell Technologies Inc, H1 2017
Fatigue - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Fatigue, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.